Value-Based Medtech Rides The Money-Go-Round Into 2016
Executive Summary
The M&A bonanza for companies in the medtech sector continued into 2015 and there is no end in sight in 2016 as manufacturers seek to augment and fine-tune portfolios to meet the new demands of payers and providers. Longer term, there are signs of a change in the top global medtech rankings.
You may also be interested in...
Cardio-Neuro Innovator LivaNova Prepares For Challenges Ahead
LivaNova was formed from the merger of cardiovascular disease therapy company Sorin Group and neuromodulation innovator Cyberonics. The role and place in the industry of this new mega group might not be obvious to all, but incoming CEO Damien McDonald already has a vision of creating a disciplined company that leverages synergies and gets closer to the customer base.
Medtechs At The Wheel In New Health Care Landscape
2016 was a year of surprise and change in political circles, but that's nothing new for the medtech industry, which over a number of years has become accustomed to health care systems demanding different and ever-higher levels of service. Smart medtechs have been ahead of the curve, but the whole industry now factors in clients' wider needs in a holistic approach to patient care. Many companies' current M&A policies are already reflecting the changes to come.
St. Jude's CardioMEMS Showing Results In HF
Results from the CHAMPION study give St. Jude hope that its CardioMEMS system will stem the tide of heart failure.